FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biochemistry, in particular, to a method for determining whether an antibody - antagonist of semaphorin 4D (SEMA4D) or an antigen-binding fragment thereof will be effective in treatment of a neurodegenerative or neuroinflammatory disease. Disclosed are a method for determining the effective dose of said antibody and a method for treating a disease associated with semaphorin 4D (SEMA4D).
EFFECT: invention allows for effective treatment of diseases associated with semaphorin 4D (SEMA4D).
25 cl, 12 dwg, 6 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF CANCER, USING ANTIBODY TO SEMAPHORIN 4D IN COMBINATION WITH EPIGENETIC MODULATING AGENT | 2018 |
|
RU2783535C2 |
| HUMAN ANTIBODIES AGAINST SEMAPHORIN 4D | 2018 |
|
RU2776443C2 |
| ANTIBODY, WHICH RECOGNIZES PEPTIDE T14 ACHE | 2016 |
|
RU2729491C2 |
| SELECTION OF PATIENTS WITH HEADACHE SUSCEPTIBLE TO ANTIBODIES AGAINST CALCITONIN GENE-RELATED PEPTIDE | 2018 |
|
RU2770066C2 |
| METHOD FOR TREATMENT OR PREVENTION OF STROKE | 2015 |
|
RU2744909C2 |
| COMPOSITIONS AND METHODS FOR INCREASING BODY WEIGHT AND LEAN MUSCLE MASS USING LEPTIN RECEPTOR ANTAGONISTS, GDF8 AND ACTIVIN A | 2019 |
|
RU2818832C2 |
| ANTIBODIES STABILIZING TREM2 | 2019 |
|
RU2807996C2 |
| COMBINATION THERAPY WITH SEMAFORIN 4D (SEMA4D) BLOCKING AND DC1 THERAPY | 2020 |
|
RU2801828C2 |
| ANTI HUMAN INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN (IL1RAP) ANTIBODIES AND USES THEREOF | 2015 |
|
RU2710787C2 |
| ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
